+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 89Years
All Genders
ID07024407

Phase 1b Study of Andecaliximab for Adults With Spinal Cord Injury at Risk of Abnormal Bone Growth Heterotopic Ossification

Led by Ashibio Inc · Updated on 2025-06-17

10

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying andecaliximab in people with recent traumatic spinal cord injury who are at risk of developing bone growth where it should not be, such as in muscles, tendons, or other soft tissues. This condition is called heterotopic ossification HO. The study aims to evaluate the safety of andecaliximab, how the drug moves through the body over time, and how it affects the body in these participants. All participants will receive weekly injections of andecaliximab under the skin during their hospital stay, clinic visits, or by self-administration if discharged. The study monitors participants over a period of up to 9 weeks, with treatment continuing during hospitalization or outpatient care. This is an open-label study, meaning all participants receive the drug and there is no placebo group. Participants will be closely monitored through safety assessments from the time they consent until four weeks after the last dose. Researchers will collect data on drug levels in the body and its biological effects throughout the study period. The study includes medical evaluations, laboratory tests, and imaging as needed, with follow-up visits to track safety and treatment impact for up to 13 weeks total.

CONDITIONS

Brief Title

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Research Team

A

ashibio ashibio Clinical Study Inquiries

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here